Loading...
TrendSpott

TrendSpott

TrendSpott
 
 
Horizon Therapeutics
100.29
+27.34%
 

HZNP

100.29
+27.34%
Horizon Therapeutics Publ
 

 
Sentiment
 
TrendSpott
3.63
Buy
 
 

63.74

61.64

81.46

108.19

 
 
1m
3m
6m
1y
 

Summary

Horizon Therapeutics Publ (HZNP) gets an overall score of 3.63 based on 35 events in the past 90 days from financial news and social media on a scale of 1 (strong sell) to 5 (strong buy). Last updated Nov 30, 2022 19:54
 

Rewards

TrendSpott

Earnings are forecast to grow

 

Risk Analysis

TrendSpott

Enter oversold territory

TrendSpott

Investors losing their confidence

 

Technical Indicators

TrendSpott

RSI is now overbought

 
 
Analysts Opinion
 
 
Earnings ×
 

Earnings

3.67
 

TrendSpott

Above analyst estimates

TrendSpott

Sales increase

TrendSpott

Earnings decline YoY

 
 
Rating ×
 

Rating

3.00
 
 
Momentum ×
 

Momentum

3.71
 

TrendSpott

Has been gaining momentum

TrendSpott

Enter oversold territory

 
Activity ×
 

Activity

3.71
 

TrendSpott

Investors losing their confidence

 
Potential ×
 

Potential

4.00
 

TrendSpott

Earnings are forecast to grow

 
 

Analysts opinion is positive and also has improved from the past 3 months

 
Street Consensus
Buy
Opinion
Trend
Score
Potential
Score
 
77%
0%
86%
100%
 
On Track
On Track
On Track
 

 

Street view is extremely ish and have postive views on the near-term outlook

 
Key Metrics
Previous
Score
Current
Score
 
Potential
NA

4.00
 
Rating
NA

3.00
 
Earnings
NA

3.67
 
Momentum
2.00

3.71
 
Activity
4.00

3.71
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
77%
9%
Positive
Negative
27 out of 35
events present
3 out of 35
events present
 

 
Events Calendar
October
S
M
T
W
T
F
S
November
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Investors Selling
Today
100.29
+27.34%
 
Strong Earnings
3 Weeks Ago
72.93
+3.70%
 
Strong Earnings
3 Weeks Ago
70.33
+11.32%
 
Weak Earnings
2 Month Ago
65.12
-1.53%
 
Latest Events

analyst forecasts $101-117/share offer price for horizon therapeutics buyout. ) confirmed it'.swith

Benzinga - analyst-ratings

Today

Activity

$100 invested in horizon therapeutics 10 years ago would be worth this much today. horizon therapeutics (nasdaq:) has outperformed the market over the past 10 years by 34.08% on an annualized basis producing an average annual return of 44.91%. currently h

Benzinga - news

Today

Activity

why horizon therapeutics stock is skyrocketing today. what happened shares of horizon therapeutics (nasdaq: hznp) were skyrocketing 27.2% higher as of 10:48 a.m. et on wednesday. the big jump came after the company announced thursday evening th

Nasdaq - News

Today

Momentum

horizon therapeutics shares jump on confirmation of takeover talks with several large companies. ) confirmed it'.s engaged inwith

Benzinga - pre-market-outlook

Today

Activity
Momentum

this is what whales are betting on horizon therapeutics. someone with a lot of money to spend has taken a bearish stance on ). and retail traders should know. we noticed this today when the big position showed up on publicly available options history th

Benzinga - markets

Today

Activity

why horizon therapeutics shares are trading higher by over 30%. here are 32 stocks moving premarket. ) shares rose 33.3% to $0.2399 in pre-market trading after jumping 45% on tuesday. kalera recently announced restructuring process for german subsidiary

Benzinga - markets

Today

Activity
Momentum

wall street expects further gains for surging horizon therapeutics stock.

Yahoo Business Finance

Today

Potential

horizon therapeutics jumps 31% as analysts comment on potential deal size.

Seeking Alpha Symbol - HZNP

Today

Activity
Momentum

horizon therapeutics confirms takeover talks with several companies (update).

Seeking Alpha Symbol - SNY

Tue Nov 29, 2022

Activity

horizon therapeutics confirms takeover talks with several companies.

Seeking Alpha Symbol - AMGN

Tue Nov 29, 2022

Activity

new research partnership with horizon therapeutics could be the next revenue catalyst for xeris. technology-based biopharma company xeris (us:xers) is set to boost its revenue with an upfront cash payment from a research collab

Nasdaq - Investing

Mon Nov 28, 2022

Activity

xeris biopharma inks research collaboration with horizon therapeutics to develop teprotumumab. (rttnews) - biopharmaceutical company xeris biopharma holdings inc. (xers) announced wednesday that it has entered into a research collaboration and o

Nasdaq Symbol - CTT

Wed Nov 23, 2022

Activity

horizons (hznp) q3 earnings & revenues surpass estimates. horizon therapeutics plc hznp reported third-quarter 2022 adjusted earnings of $1.25 per share which beat the zacks consensus estimate of $1.00. the company reported adjusted earnings of

Nasdaq Symbol - AKRO

Thu Nov 3, 2022

Earnings

why horizon therapeutics shares rose 11.32% on wednesday. what happened horizon therapeutics (nasdaq: hznp) a biopharmaceutical company that specializes in rare autoimmune and inflammatory diseases saw its shares jump 11.32% on wednesday after the compan

Nasdaq Symbol - AZN

Thu Nov 3, 2022

Momentum

horizon therapeutics (hznp) q3 earnings and revenues beat estimates. horizon therapeutics (hznp) came out with quarterly earnings of $1.25 per share beating the zacks consensus estimate of $1 per share. this compares to earnings of $1.75 per sha

Nasdaq - Investing

Wed Nov 2, 2022

Earnings

horizon therapeutics reports q3 earnings beat. raises fy22 guidance & peak annual net sales expectations.

Seeking Alpha Symbol - HZNP

Wed Nov 2, 2022

Earnings
Potential

horizon therapeutics gains as strong sales for arthritis therapy prompt guidance raise.

Seeking Alpha Symbol - HZNP

Wed Nov 2, 2022

Earnings
Momentum
Potential

horizon therapeutics does not have meaningful upside analyst initiating coverage says. ) with a neutral rating and. the analyst writes that horizon deserves cr

Benzinga - analyst-ratings

Tue Nov 1, 2022

Rating

analysts estimate horizon therapeutics (hznp) to report a decline in earnings: what to look out for. wall street expects a year-over-year decline in earnings on lower revenues when horizon therapeutics (hznp) reports results for the quarter ende

Nasdaq Symbol - HZNP

Wed Oct 26, 2022

Earnings

horizon therapeutics cuts fy adj. ebitda guidance to reflect new milestone related expense.

Seeking Alpha Symbol - HZNP

Fri Oct 7, 2022

Activity

horizon (hznp) completes enrollment in phase iv ted study. horizon therapeutics plc hznp announced that it has completed enrollment in the phase iv study evaluating its marketed drug tepezza (teprotumumab-trbw) for the treatment of thyroid eye d

Nasdaq Symbol - APTO

Fri Sep 30, 2022

Activity

horizon therapeutics to buyback up to $500 mln of ordinary shares. (rttnews) - biotechnology company horizon therapeutics plc (hznp) today announced that its board of directors authorized the repurchase of up to $500 million of the companys ordinary share

Nasdaq - HZNP

Fri Sep 9, 2022

Activity

horizon therapeutics announces $500m buyback program.

Seeking Alpha - HZNP

Fri Sep 9, 2022

Activity

horizon therapeutics is now oversold (hznp). legendary investor warren buffett advises to be fearful when others are greedy and be greedy when others are fearful. one way we can try to measure the level of fear in a given stock is through a technical

Nasdaq - Markets

Fri Sep 2, 2022

Momentum

 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits
 

Receive our daily HZNP alerts

Enter your email to receive daily alerts

SECURITY POWERED BY

secure
guaranteed
 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
TrendSpott

TrendSpott

Get the pulse of the market

 
TrendSpott

TrendSpott BETA

HZNP
Horizon Therapeutics Publ
100.29
+27.34%
 
 
 

Recently Viewed

 

HZNP

Horizon Therapeutics Publ

 
 
 

Summary

Horizon Therapeutics Publ (HZNP) gets an overall score of 3.63 based on 35 events in the past 90 days from financial news and social media on a scale of 1 (strong sell) to 5 (strong buy). Last updated Nov 30, 2022 19:54

 
 
63.74
61.64
81.46
108.19
 
 
1m
3m
6m
1y
 
Sentiment
 
TrendSpott
Total score
3.63
Buy

Rewards

TrendSpott

Earnings are forecast to grow

Risk Analysis

TrendSpott

Enter oversold territory

TrendSpott

Investors losing their confidence

Technical Indicators

TrendSpott

RSI is now overbought

 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
0%
86%
100%
On Track
On Track
On Track
 
77%
9%
Positive
Negative
27 out of 35
events present
3 out of 35
events present
 

Street view is extremely ish and have postive views on the near-term outlook

 
 
Analysts Opinion
 
 
Earnings ×
 

Earnings

3.67
 

TrendSpott

Above analyst estimates

TrendSpott

Sales increase

TrendSpott

Earnings decline YoY

 
 
Rating ×
 

Rating

3.00
 
 
Momentum ×
 

Momentum

3.71
 

TrendSpott

Has been gaining momentum

TrendSpott

Enter oversold territory

 
Activity ×
 

Activity

3.71
 

TrendSpott

Investors losing their confidence

 
Potential ×
 

Potential

4.00
 

TrendSpott

Earnings are forecast to grow

 
 

Analysts opinion is positive and also has improved from the past 3 months

 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Events Calendar
 
October
S
M
T
W
T
F
S
 
 
 
November
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change
 
Investors Selling
Today
100.29
+27.34%
 
Strong Earnings
3 Weeks Ago
72.93
+3.70%
 
Strong Earnings
3 Weeks Ago
70.33
+11.32%
 
Weak Earnings
2 Month Ago
65.12
-1.53%
 
 
 
TrendSpott

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

TrendSpott on Twitter TrendSpott on YouTube TrendSpott on stocktwits

 

Receive our daily HZNP Alerts

Enter your email to receive daily alerts

 

SECURITY POWERED BY

TrendSpott
TrendSpott
 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by TrendSpott including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines